The mystery of how certain genetic mutations lead to Type 1 diabetes, which has baffled scientists for over 40 years, has finally been solved by The Scripps Research Institute.
According to researchers, their findings could lead to novel therapies for Type 1 diabetes and other autoimmune diseases."People have been looking for the mechanism linking HLA and autoimmunity for 40 years. This study provides a big leap forward in understanding and suggests a critical new target to intervene in type 1 diabetes," said Scripps Research Professor Luc Teyton, who led the study with Scripps Research Professor Ian Wilson.
While genes predispose people to many different types of diseases in many different ways, specific genetic variations are especially strong predictor of the development of type 1 diabetes.
Three genetic variations in particular (HLA-DQ2, HLA-DQ8, and HLA-DR0405)-all located in the region of the genome called HLA for "human leukocyte antigen"-are known to dramatically increase risk of coming down with the condition.
These three genes encode molecules that present peptides (protein fragments) to the body's T cells. T cells then determine whether the peptide being presented is dangerous and needs to be eliminated from the body-as in the case of foreign invaders such as bacteria or viruses-or whether the peptide is "self," part of the host and something the immune system needs to leave alone. However, in the context of type 1 diabetes, T cells aggressively attack the body's own cells.
The scientists wanted to know on a molecular level how mutations in the immune surveillance machinery could lead to type 1 diabetes.
Advertisement
In the new research, the team used a series of structural and biophysical studies to answer that question.
Advertisement
Source-ANI
TAN